Ilia I. Ouspenski

Array ( [id] => 14639109 [patent_doc_number] => 10364287 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Anti-CD28 humanized antibodies [patent_app_type] => utility [patent_app_number] => 15/386998 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 7051 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706267 [patent_doc_number] => 20170174767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'ICOS BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/387161 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 51929 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15387161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733267 [patent_doc_number] => 20180371101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => INTRAVESICAL THERAPY FOR BLADDER CANCER [patent_app_type] => utility [patent_app_number] => 16/063169 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16063169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15227667 [patent_doc_number] => 10501544 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Anti-B7-H3 antibodies and diagnostic uses thereof [patent_app_type] => utility [patent_app_number] => 15/363992 [patent_app_country] => US [patent_app_date] => 2016-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 19105 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15363992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16985501 [patent_doc_number] => 11072657 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-27 [patent_title] => Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody [patent_app_type] => utility [patent_app_number] => 15/776732 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 14 [patent_no_of_words] => 21112 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11548507 [patent_doc_number] => 09617338 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-04-11 [patent_title] => 'Antibodies and immunocytokines' [patent_app_type] => utility [patent_app_number] => 15/354971 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 27 [patent_no_of_words] => 92272 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15354971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14794093 [patent_doc_number] => 10400039 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-03 [patent_title] => Targeted binding agents against B7-H1 [patent_app_type] => utility [patent_app_number] => 15/333683 [patent_app_country] => US [patent_app_date] => 2016-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 45709 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15333683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17306310 [patent_doc_number] => 11207393 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Regulatory T cell PD-1 modulation for regulating T cell effector immune responses [patent_app_type] => utility [patent_app_number] => 15/768077 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 13 [patent_no_of_words] => 62070 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11641006 [patent_doc_number] => 09662354 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-30 [patent_title] => 'Compositions, methods, and computer systems related to making and administering modified T cells' [patent_app_type] => utility [patent_app_number] => 15/290043 [patent_app_country] => US [patent_app_date] => 2016-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 20103 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15290043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14975537 [patent_doc_number] => 10441655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Monoclonal antibodies to programmed death 1 (PD-1) [patent_app_type] => utility [patent_app_number] => 15/288545 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 100 [patent_no_of_words] => 46084 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15288545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16892032 [patent_doc_number] => 11033559 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-15 [patent_title] => Leukocyte infiltration promoting agent and antitumor immunostimulatory agent [patent_app_type] => utility [patent_app_number] => 15/762644 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 9520 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15762644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14913677 [patent_doc_number] => 10428145 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-01 [patent_title] => PD-1 binding proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/278425 [patent_app_country] => US [patent_app_date] => 2016-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 27 [patent_no_of_words] => 86983 [patent_no_of_claims] => 155 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15278425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17633900 [patent_doc_number] => 11344605 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Therapeutic use of inhibitors of t cell activation or stimulation [patent_app_type] => utility [patent_app_number] => 16/069676 [patent_app_country] => US [patent_app_date] => 2016-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 69 [patent_no_of_words] => 23006 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16069676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461745 [patent_doc_number] => 20180282415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer [patent_app_type] => utility [patent_app_number] => 15/765149 [patent_app_country] => US [patent_app_date] => 2016-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15765149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17104373 [patent_doc_number] => 11124569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-21 [patent_title] => Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors [patent_app_type] => utility [patent_app_number] => 15/758515 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 8 [patent_no_of_words] => 44972 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15758515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15309093 [patent_doc_number] => 10519237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS [patent_app_type] => utility [patent_app_number] => 15/261945 [patent_app_country] => US [patent_app_date] => 2016-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 76 [patent_no_of_words] => 28380 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15261945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11480499 [patent_doc_number] => 09587030 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'Anti-hOX40L antibodies, uses, and methods' [patent_app_type] => utility [patent_app_number] => 15/259553 [patent_app_country] => US [patent_app_date] => 2016-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 69513 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15259553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883595 [patent_doc_number] => 10421824 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Proteins specific for BAFF and B7RP1 [patent_app_type] => utility [patent_app_number] => 15/258750 [patent_app_country] => US [patent_app_date] => 2016-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 13898 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15258750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514335 [patent_doc_number] => 20170081409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/254315 [patent_app_country] => US [patent_app_date] => 2016-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 45682 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15254315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421381 [patent_doc_number] => 20170029525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER' [patent_app_type] => utility [patent_app_number] => 15/252267 [patent_app_country] => US [patent_app_date] => 2016-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 9398 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15252267 [rel_patent_id] =>[rel_patent_doc_number] =>)